Cell Cycle Aberration in Ameloblastoma: as Evidenced by an Immunohistochemical Expression  of P53 and Survivin

Dr. Zulfin Shaikh; Dr. Niranjan K C

Authors

Dr. Zulfin Shaikh
Dr. Niranjan K C

Keywords:

apoptosis, survivin, p53, ameloblastoma, immunohistochemical expression, tumorigenesis, aberrations, tumour suppressor gene, inhibitor of apoptosis pr

Abstract

Evasion from apoptosis by aberrations of apoptotic regulatory factors has been found to cause accumulation of neoplastic cells in various tumours. Survivin, an inhibitor of apoptosis protein localizes to the nucleus as well as in the cytoplasm depending on its function such as cell division and inhibiting apoptosis. The regulation of Survivin seems to be linked to p53, a tumour suppressor gene. Though there are studies showing the role of p53 and Survivin in oral carcinogenesis, but the field of odontogenic tumours yet needs to be explored. The aim of this study was to correlate the expression of p53 and Survivin in normal tissues (tooth germ) and Ameloblastoma as well as to assess differential localization of Survivin. Qualitative and quantitative assess-ment of immunexpression of p53 and Survivin (nuclear and cytoplasmic) was evaluated in a total of 35 cases which included 10 tooth germs and 25 Ameloblastoma. The expression levels of p53 and nuclear Survivin were significantly higher in Ameloblastoma quantitatively but there was no significant correlation between p53 and cytoplasmic expression of Survivin.

Downloads

How to Cite

Cell Cycle Aberration in Ameloblastoma: as Evidenced by an Immunohistochemical Expression of P53 and Survivin. (2014). Global Journal of Medical Research, 14(49), 31-37. https://medicalresearchjournal.org/index.php/GJMR/article/view/

Download Citation

References

Hiroyuki Kumamoto (2010) Molecular alterations in the development and progression of odontogenic tumors. 14(4), 121-130. https://doi.org/10.3353/omp.14.121

H. Kumamoto (2006) Molecular pathology of odontogenic tumors. 35(2), 65-74. https://doi.org/10.1111/j.1600-0714.2006.00380.x

H. Philipsen (2005) WHO Classification of Tumors: Pathology and genetics of head and neck tumors.

Li F, Ambrosini G, Chu EY (1998) Control of apoptosis and mitotic spindle checkpoint by survivin. 396(6711), 580-584. https://doi.org/10.1038/25141

Miller C, Mohandas T, Wolfd D (1986) Human p53 gene localized to short arm of chromosome 17. 319(6056), 783-784. https://doi.org/10.1038/319783a0

L. Loro, O. Vintermyr, A. Johannessen (2005) Apoptosis in normal and diseased oral tissues. 11(5), 274-287. https://doi.org/10.1111/j.1601-0825.2005.01117.x

Yigong Shi (2000) Survivin structure: crystal unclear. 7(8), 620-623. https://doi.org/10.1038/77904

Dario Altieri (2006) The case for survivin as a regulator of microtubule dynamics and cell-death decisions. 18(6), 609-615. https://doi.org/10.1016/j.ceb.2006.08.015

Shirley Knauer, Wolf Mann, Roland Stauber (2007) Survivin's Dual Role: An Export's View. 6(5), 518-521. https://doi.org/10.4161/cc.6.5.3902

Roland Stauber, Wolf Mann, Shirley Knauer (2007) Nuclear and Cytoplasmic Survivin: Molecular Mechanism, Prognostic, and Therapeutic Potential. 67(13), 5999-6002. https://doi.org/10.1158/0008-5472.can-07-0494

Knauer SK, Krämer OH, Knösel T (2007) Nuclear export is essential for the tumor‐promoting activity of survivin. 21(1), 207-216. https://doi.org/10.1096/fj.06-5741com

G. Qi, H. Tuncel, E. Aoki (2009) Intracellular localization of survivin determines biological behavior in colorectal cancer. 22, 557-562.

Li F, Yang J, Ramnath N (2005) Nuclear or cytoplasmic expression of survivin: What is the significance?. 114(4), 509-512. https://doi.org/10.1002/ijc.20768

Mirza A, McGuirk M, Hockenberry TN (2002) Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. 21(17), 2613-2622. https://doi.org/10.1038/sj.onc.1205353

G. Lo Muzio, Pannone, Staibano (2003) Survivin expression in oral squamous cell carcinoma. 89, 2244-2248.

Chen P, Li J, Ge LP (2010) Prognostic value of survivin, X-linked inhibitor of apoptosis protein and second mitochondria-derived activator of caspases expression in advanced non-small-cell lung cancer patients. 15(3), 501-509. https://doi.org/10.1111/j.1440-1843.2010.01710.x

J. Choi, H. Chang (2012) The expression of MAGE and SSX, and correlation of COX2, VEGF, and survivin in colorectal cancer. 32, 559-564.

Nassar A, Sexton D, Cotsonis G (2008) Survivin Expression in Breast Carcinoma: Correlation With Apoptosis and Prognosis. 16(3), 221-226. https://doi.org/10.1097/pai.0b013e3180c317bc

Kim JY, Chung JY, Lee SG (2006) Nuclear interaction of Smac/DIABLO with Survivin at G2/M arrest prompts docetaxel-induced apoptosis in DU145 prostate cancer cells. 350(4), 949-954. https://doi.org/10.1016/j.bbrc.2006.09.143

Ito T, Shiraki K, Sugimoto K (2000) Survivin promotes cell proliferation in human hepatocellular carcinoma. 31(5), 1080-1085. https://doi.org/10.1053/he.2000.6496

Shintani M, Sangawa A, Yamao N (2013) Immunohistochemical expression of nuclear and cytoplasmic survivin in gastrointestinal carcinoma. 6, 2919-2927.

deOliveira MG, da I, Chaves ACM (2010) Odontogenic Epithelium: Immunolabeling of Ki-67, EGFR and Survivin in Pericoronal Follicles, Dentigerous Cysts and Keratocystic Odontogenic Tumors. 5(1), 1-7. https://doi.org/10.1007/s12105-010-0216-0

Kumamoto H, Ooya K (2004) Expression of survivin and X chromosome-linked inhibitor of apoptosis protein in ameloblastomas. 444, 164-170.

Andric M, Dozic B, Popovic B (2010) Survivin expression in odontogenic keratocysts and correlation with cytomegalovirus infection. 16(2), 156-159. https://doi.org/10.1111/j.1601-0825.2009.01612.x

Barboza CA, Pereira L, Freitas A (2005) Proliferating cell nuclear antigen (PCNA) and p53 protein expression in ameloblastoma and adenomatoid adontogenic tumor. 16(1), 56-61.

Carvalhais JN, de Aguiar, de VC (1995) p53 and MDM2 expression in odontogenic cysts and tumours. 5(3), 218-222. https://doi.org/10.1111/j.1601-0825.1999.tb00304.x

Susanne Lens, Gerben Vader, René Medema (2006) The case for Survivin as mitotic regulator. 18(6), 616-622. https://doi.org/10.1016/j.ceb.2006.08.016

Knauer SK, Bier C, Habtemichael N (2006) The Survivin-Crm1 interaction is essential for chromosomal passenger complex localization and function. 7(12), 1259-1265. https://doi.org/10.1038/sj.embor.7400824

F. Li (2005) Role of surviving and its splice variants in tumorigenesis. 92(2), 212-216. https://doi.org/10.1038/sj.bjc.6602340

Parenti A, Leo G, Porzionato A (2006) Expression of survivin, p53, and caspase 3 in Barrett's esophagus carcinogenesis. 37(1), 16-22. https://doi.org/10.1016/j.humpath.2005.10.003

Adamkov M, Halasova E, Rajcani J (2011) Relation between expression pattern of p53 and survivin in cutaneous basal cell carcinomas. 17(3), BR74-BR80. https://doi.org/10.12659/msm.881442

K. Ranade, A. Nerurkar, M. Phulpagar (2009) Expression of Survivin and p53 proteins and their correlation with hormone receptor status in Indian breast cancer patients. 63, 481-490.

Halasova E, Adamkov M, Kavcova E (2009) Expression of anti-apoptotic protein survivin and tumor suppressor p53 protein in patients with pulmonary carcinoma. 14, 97-100.

N. El-Sissy (1999) Immunohistochemical detection of p53 protein in ameloblastoma types. 5(3), 478-489. https://doi.org/10.26719/1999.5.3.478

K. Al-Salihi, L. Li, A. Azlina (2006) P53 gene mutation and protein expression in ameloblastomas. 5, 1034-1040.

Hollstein M, Sidransky D, Vogelstein B (1991) p53 Mutations in Human Cancers. 253(5015), 49-53. https://doi.org/10.1126/science.1905840

Al-Fayad DWS (2010) Immunohistochemical Expression of P53 in Different Types of Ameloblastoma. 8, 66-73.

L. Bai, W. Zhu (2006) p53: Structure, Function and Therapeutic Applications. 2, 141-153.

Dario Altieri (2003) Survivin, versatile modulation of cell division and apoptosis in cancer. 22(53), 8581-8589. https://doi.org/10.1038/sj.onc.1207113